Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Immunogenicity of Intas Denosumab vs Prolia in Postmenopausal Osteoporosis
NCT05419427Phase 3Recruiting
- Sponsor
- Lambda Therapeutic Research
- Start
- Nov 2021
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of INTP23 in postmenopausal osteoporosis (2 arms), sponsored by Lambda Therapeutic Research. Primary endpoints: Maximum measured concentration, Area under the concentration versus time curve from time zero to the last measurable concentration and 1 more. Started Nov 2021; status: recruiting.
02
Drugs
INTP23
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT05419427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05419427.